Tag Archives: Tim Chiang

Northland Securities Maintains Their Buy Rating on Kala Pharmaceuticals (KALA)

In a report released today, Tim Chiang from Northland Securities maintained a Buy rating on Kala Pharmaceuticals (KALA – Research Report), with a price target of $17.00. The company’s shares closed last Friday at $7.30. According to TipRanks.com, Chiang is

Northland Securities Maintains Their Buy Rating on IDEAYA Biosciences (IDYA)

In a report released today, Tim Chiang from Northland Securities maintained a Buy rating on IDEAYA Biosciences (IDYA – Research Report), with a price target of $28.00. The company’s shares closed last Tuesday at $13.08. According to TipRanks.com, Chiang is

Northland Securities Reaffirms Their Buy Rating on VYNE Therapeutics (VYNE)

Northland Securities analyst Tim Chiang maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report) today and set a price target of $6.00. The company’s shares closed last Thursday at $1.62. According to TipRanks.com, Chiang is a 1-star analyst

Northland Securities Remains a Buy on IDEAYA Biosciences (IDYA)

Northland Securities analyst Tim Chiang reiterated a Buy rating on IDEAYA Biosciences (IDYA – Research Report) today and set a price target of $28.00. The company’s shares closed last Friday at $11.63. According to TipRanks.com, Chiang is a 1-star analyst

What Made Northland Securities Upgrade Pacira Pharmaceuticals’ Stock?

In a report released today, Tim Chiang from Northland Securities upgraded Pacira Pharmaceuticals (PCRX – Research Report) to Buy, with a price target of $67.00. The company’s shares closed last Friday at $60.77, close to its 52-week high of $64.44.

Northland Securities Keeps a Buy Rating on Kala Pharmaceuticals (KALA)

In a report released yesterday, Tim Chiang from Northland Securities maintained a Buy rating on Kala Pharmaceuticals (KALA – Research Report), with a price target of $17.00. The company’s shares closed last Tuesday at $8.05. According to TipRanks.com, Chiang is